Fecal transplants successful for treating C. difficile infection

March 30, 2015, BioMed Central

Distasteful though it sounds, the transplantation of fecal matter is more successful for treating Clostridium difficile infections than previously thought.

The research, published in the open access journal Microbiome, reveals that healthy changes to a patient's microbiome are sustained for up to 21 weeks after , and has implications for the regulation of the treatment.

Clostridium difficile infections are a growing problem, leading to recurrent cases of diarrhea and severe abdominal pain, with thousands of fatalities worldwide every year. The infection is thought to work by overrunning the intestinal microbiome - the ecosystem of microorganisms that maintain a healthy intestine.

Fecal microbiota transplantation was developed as a method of treating C. difficile infection, and is particularly successful in patients who suffer repeat infections. Fecal matter is collected from a donor, purified, mixed with a saline solution and placed in a patient, usually by colonoscopy.

Previous research has shown that the fecal microbiota of patients resembles that of the donor, but not much is known about the short and long term stability of fecal microbiota transplanted into recipients.

In this research, Michael Sadowsky and colleagues at the University of Minnesota collected from four patients before and after their . Three patients received freshly prepared microbiota from fecal matter and one patient received fecal microbiota that had previously been frozen. All received fecal microbiota from the same pre-qualified donor.

The team compared the pre- and post-transplant fecal microbial communities from the four patients, as well as from 10 additional with recurring C. difficile infections, to the sequences of normal subjects described in the Human Microbiome Project. In addition, they looked at the changes in fecal bacterial composition in recipients over time, and compared this to the changes observed within samples from the donor.

Surprisingly, after transplantation, patient samples appeared to sustain changes in their microbiome for up to 21 weeks and remained within the spectrum of fecal microbiota characterized as healthy.

Michael Sadowsky says: "Our study shows that there are both short and long term changes in the fecal microbiome following transplantation. The diversity and types of microbes present fall into a cloud of possibilities represented by those of 'normal fecal microbiota'. While we have many similarities in fecal microbiota amongst humans in general, there are individual differences that make us all unique, but do not effect apparent gut functioning."

The authors say that the research could have regulatory implications for fecal transplantations. This is because the US Food and Drug Administration has determined that fecal microbiota constitutes a 'drug', and has stated that compositional certainty is going to be important. The dynamic nature of fecal microbiota seen in both the donor and the recipients suggest that this framework of regulation may not be applicable for fecal transplantations.

Explore further: Fecal microbiota tx feasible for recurrent C. difficile in HIV

More information: Alexa Weingarden, Antonio Gonzalez, Yoshiki Vazquez-Baeza, Sophie Weiss, Gregory Humphrey, Donna Berg-Lyons, Dan Knights, Tatsuya Unno, Aleh Bobr, Johnthomas Kang, Alexander Khoruts, Rob Knight and Michael J Sadowsky, Dynamic Changes in Short- and Long-Term Bacterial Composition Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection, Microbiome 2015, DOI: 10.1186/s40168-015-0070-0

Related Stories

Fecal microbiota tx feasible for recurrent C. difficile in HIV

May 22, 2013
(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Internal Medicine.

Understanding intestinal microbiota to regain balance in the gut

December 12, 2014
The human gut is its own ecosystem, hosting close to a thousand microorganisms, many of which are helpful and necessary.

IDSA: Oral ingestion viable for fecal microbiome transplant

October 3, 2013
(HealthDay)—For patients with recurrent Clostridium difficile infection (rCDI), fecal microbiome transplantation via ingestion of fecal microbes is well-tolerated and arrests rCDI, according to a study presented at the ...

Fecal transplant feasible for recurrent C. difficile infection

March 3, 2012
(HealthDay) -- Recurrent Clostridium difficile (C. difficile) infection (CDI) can successfully be treated in the vast majority of patients through a fecal transplantation procedure via colonoscopy, according to research published ...

Rapid and unexpected weight gain after fecal transplant

February 4, 2015
A woman successfully treated for a recurrent Clostridium difficile infection with stool from an overweight donor rapidly gained weight herself afterwards, becoming obese, according to a case report published in the new journal ...

A new treatment option for Clostridium difficile: Fecal transplantation

March 14, 2012
Fecal transplantation through colonoscopy is an effective treatment for recurrent Clostridium difficile infection (CDI), according to a new study in Gastroenterology, the official journal of the American Gastroenterological ...

Recommended for you

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

Infectivity of different HIV-1 strains may depend on which cell receptors they target

December 6, 2018
Distinct HIV-1 strains may differ in the nature of the CCR5 molecules to which they bind, affecting which cells they can infect and their ability to enter cells, according to a study published December 6 in the open-access ...

Protecting cell powerhouse paves way to better treatment of acute kidney injury

December 6, 2018
For the first time, scientists have described the body's natural mechanism for temporarily protecting the powerhouses of kidney cells when injury or disease means they aren't getting enough blood or oxygen.

New study uncovers why Rift Valley fever is catastrophic to developing fetuses

December 5, 2018
Like Zika, infection with Rift Valley fever virus can go unnoticed during pregnancy, all the while doing irreparable—often lethal—harm to the fetus. The results of a new study, led by researchers at the University of ...

Study highlights potential role of bioaerosol sampling to address airborne biological threats

December 5, 2018
As a leading global city with a high population density, Singapore is vulnerable to the introduction of biological threats. Initiating an early emergency response to such threats calls for the rapid identification of the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.